Waldenström macroglobulinemia: the mystery of one clinical case

December 12, 2023
448
УДК:  616-006.44
Resume

The clinical case of Waldenström macroglobulinemia with peripheral neuropathy of lower extremities is presented. The course of the disease, symptoms, diagnostic pathway and treatment management are described.

References

  • 1. Ghobrial I.M., Witzig T.E. (2004) Waldenstrom macroglobulinemia. Curr. Treat Options Oncol., 5(3): 239–247. DOI: 10.1007/s11864-004-0015-5.
  • 2. Harris N.L., Jaffe E.S., Diebold J. et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J. Clin. Oncol., 17: 3835–3849.
  • 3. Waldenström J. (1944) Incipient myelomatosis or «essential» hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med. Scandinavica, 117: 216–222.
  • 4. Leleu X., Gay J., Roccaro A.M. et al. (2009) Update on therapeutic options in Waldenström macroglobulinemia. Eur. J. Haematol., 82(1): 1–12.
  • 5. Ghobrial I.M., Gertz M.A., Fonseca R. (2003) Waldenstrom macroglobulinaemia. Lancet Oncol., 4: 679–685.
  • 6. Ghobrial I.M. , Fonseca R., Gertz M.A. et al. (2006) Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br. J. Haematol., 133: 158–164.
  • 7. Hunter Z.R., Xu L., Yang G. et al. (2013) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 123(11): 1637–1646. doi: 10.1182/blood-2013-09-525808.
  • 8. Castillo J.J., Moreno D.F., Arbelaez Z.R., Treon S.P. (2019) CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: a systematic review. Exp. Rev. Hematol., 12(10): 873–881.
  • 9. Koshiol J., Gridley G., Engels E. et al. (2008) Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch. Int. Med., 168(17): 1903–1909.
  • 10. Kristinsson S., Björkholm M. et al. (2008) Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood, 112: 3052–3056.
  • 11. Royer R., Koshiol J. et al. (2010) Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood, 115: 4464–4471.
  • 12. Baehring J.M., Hochberg E.P., Raje N. et al. (2008) Neurological manifestations of Waldenström macroglobulinemia. Nat. Clin. Pract. Neurol., 4: 547–556.
  • 13. Castillo J.J., Garcia-Sanz R., Hatjiharissi E. et al. (2016) Recommendations for the diagnosis and initial evaluation of patients with Waldenström macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br. J. Haematol., 175(1): 77–86.
  • 14. Sallman D.A., Chaudhury A., Nguyen J. et al. (2021) List. Handbook of Hematologic Malignancies, 2nd еd., 220 р.
  • 15. Castillo J.J., Treon S.P. (2020) Management of Waldenström macroglobulinemia in 2020. Hematology Am. Soc. Hematol. Educ. Program, 1: 372–379.
  • 16. http://www.dec.gov.ua/wp-content/uploads/2019/11/2013_866_ykpmd_limfomy.pdf.